Mereo BioPharma (MREO) Shares Outstanding (Weighted Average) (2017 - 2026)

Mereo BioPharma (MREO) has 10 years of Shares Outstanding (Weighted Average) data on file, last reported at $801.8 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $801.8 million, up 2.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $801.8 million (up 2.23% YoY), and the FY2025 annual result was $797.1 million, up 7.77% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $801.8 million in Q1 2026 per MREO's latest filing, from $797.1 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $801.8 million in Q1 2026 and troughed at $623.9 million in Q1 2023.
• A 5-year average of $730.3 million and a median of $733.7 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) retreated 6.79% in 2023, then gained 22.55% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $707.5 million in 2022, then declined by 6.79% to $659.5 million in 2023, then grew by 12.16% to $739.6 million in 2024, then grew by 7.77% to $797.1 million in 2025, then grew by 0.59% to $801.8 million in 2026.
• Business Quant data shows MREO's Shares Outstanding (Weighted Average) at $801.8 million in Q1 2026, $797.1 million in Q4 2025, and $799.9 million in Q3 2025.